Keywords: Germany, Orphan drugs, Pricing, vfa bio, VFA

German biotech calls for fair treatment of orphan drugs

Article | 17 June 2011

Orphan drugs are a rapidly expanding subsector of the pharmaceuticals industry. Martina Ochel, chief executive of Genzyme and acting chairman ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in